Mumbai: Morepen Laboratories Limited has commenced commercial supplies under its recently announced ₹825 crore contract development and manufacturing organisation (CDMO) mandate, with the first dispatch worth about ₹50 crore completed during the first quarter of FY27, the company said on Tuesday.
The Gurugram-based pharmaceutical company said the initial shipment marks the transition of the multi-year manufacturing programme from the validation and qualification stage to commercial execution.
Following the first dispatch, Morepen expects to scale up supplies under the mandate, with additional deliveries worth around ₹225 crore planned during the second quarter of FY27, subject to customer schedules and regulatory and commercial requirements.
Commenting on the development, Sanjay Suri, Managing Director of Morepen Laboratories, said the milestone reflects the company’s shift towards long-term global manufacturing partnerships. He added that the company has worked closely with the customer on validation, manufacturing readiness and supply chain planning and is now focused on expanding its CDMO platform across additional customers and products.
To support the ramp-up in manufacturing, the company said it is expanding its production infrastructure. Morepen expects its total reactor capacity to increase to around 600 kilolitres by the end of the second quarter, with further expansion planned to 800 kilolitres and eventually 1,000 kilolitres in subsequent phases.
Morepen Laboratories Limited manufactures active pharmaceutical ingredients (APIs), formulations, home diagnostic products and over-the-counter healthcare products. The company has been expanding its CDMO business as part of its strategy to deepen relationships with global pharmaceutical customers and diversify its revenue base through long-term manufacturing partnerships.